Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

INDIANAPOLIS, Feb. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced its financial results for the fourth quarter of 2022. "2023 is an inflection point for Lilly - a chance to ...

We are increasing Eli Lilly’s fair value estimate to $500 from $450 following solid fourth-quarter results with robust sales from diabetes drug Mounjaro and strong pipeline advancements running ...

The transaction will allow Lilly to expand its pain management pipeline with the addition of STC-004, a Phase 2-ready Nav1.8 inhibitor being studied for the treatment of pain.

Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clinical-phase Alzheimer’s disease and obesity candidates as part of its quarterly clear-out. The removal of ...